Abstract #0233

Semi-quantitative MRI Assessment of anti-PD1 Immunotherapy Response in Recurrent Glioblastoma

Lei Qin^1,2, Xiang Li^2,3, Amanda Stroiney⁴, David A Reardon^1,2, and Geoffrey Young^2,3

¹Dana-Farber Cancer Institute, boston, MA, United States, ²Harvard Medical School, boston, MA, United States, ³Brigham and Women's Hospital, Boston, MA, United States, ⁴Northeastern University, Boston, MA, United States

The purpose of this study is to evaluate the predictive value of quantitative and semi-quantitative MRI biomarkers in determining patient benefit in anti-PD1 immunotherapy treatments. Longitudinal MRIs were performed on patients diagnosed with recurrent GBM. Volumetric analysis of abnormal tissue from contrast enhanced T1, FLAIR, and ADC revealed two distinct patterns: a) progressive increase volume in patients who derived no significant benefit, and b) a transient increase in the volume, followed by a delayed decrease in patients with >6 mo survival on trial. In this preliminary study (n=10), the data suggest that the volume of abnormal tissue on ADC seems to correlate better with patient benefit than abnormality on FLAIR and T1.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.